University of Oslo studying intranasal delivery of oxytocin; Sancilio Pharma files for IPO worth up to $86M;

> Researchers at the University of Oslo are collaborating with Optinose for the intranasal delivery of oxytocin, which research shows helps to improve perception of social cues, making it potentially useful among autistic patients. More

> Sancilio Pharmaceuticals just filed with the SEC to raise up to $86 million in an IPO on the Nasdaq. It licenses and develops products based on its lipid drug delivery technology. More

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.